Changes in survival and time to progression in metastatic breast cancer (MBC) patients enrolled into clinical trials from 1983 to 2001.

被引：0
|
作者：
Gennari, A
Conte, P
Orlandini, C
Guarneri, V
Rosso, R
Bruzzi, P
机构：
[1] Div Med Oncol, Pisa, Italy
[2] Div Med Oncol, Modena, Italy
[3] NCI, Genoa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
634
引用
收藏
页码：35S / 35S
页数：1
相关论文
共 50 条
  • [11] Overall survival and time to disease progression improved in metastatic breast cancer patients
    不详
    ONCOLOGY-NEW YORK, 2004, 18 (03): : 338 - 338
  • [12] Validation of prognostic scores in patients with metastatic bladder carcinoma (mBC) enrolled in early phase clinical trials
    Alhalabi, O.
    Hahn, A. W.
    Msaouel, P.
    Meric-Bernstam, F.
    Naing, A.
    Piha-Paul, S.
    Janku, F.
    Pant, S.
    Yap, T. A.
    Hong, D. S.
    Fu, S.
    Karp, D. D.
    Campbell, E.
    Campbell, M. T.
    Shah, A. Y.
    Tannir, N.
    Siefker-Radtke, A. O.
    Gao, J.
    Roszik, J.
    Subbiah, V.
    ANNALS OF ONCOLOGY, 2020, 31 : S597 - S598
  • [13] Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer
    Sara A. Hurvitz
    Deepa Lalla
    Ross D. Crosby
    Susan D. Mathias
    Breast Cancer Research and Treatment, 2013, 142 : 603 - 609
  • [14] Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer
    Hurvitz, Sara A.
    Lalla, Deepa
    Crosby, Ross D.
    Mathias, Susan D.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 142 (03) : 603 - 609
  • [15] Patients with metastatic breast cancer enrolled in phase I clinical trials: Clinical outcomes and cohort trends.
    Weiss, Jennifer
    Gao, Dexiang
    Elias, Anthony D.
    Borges, Virginia F.
    Kabos, Peter
    Davis, S. Lindsey
    Leong, Stephen
    Diamond, Jennifer Robinson
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [16] Tailored endpoints: A proposal for design of future clinical trials in metastatic breast cancer (MBC).
    Fontanella, Caterina
    Bonotto, Marta
    Driol, Pamela
    Valent, Francesca
    Gerratana, Lorenzo
    Russo, Stefania
    Andreetta, Claudia
    Minisini, Alessandro
    Mansutti, Mauro
    Sottile, Roberta
    Fasola, Gianpiero
    Puglisi, Fabio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [17] The impact of quality of life (QL) scores on survival in patients with metastatic breast cancer (MBC)
    Coates, A
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S39 - S39
  • [18] Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC)
    Stemmler, HJ
    Kahlert, S
    Siekieraa, W
    Untch, M
    Heinrich, B
    Heinemann, V
    ONKOLOGIE, 2005, 28 (11): : 582 - 586
  • [19] Improved survival outcomes among cervical cancer patients enrolled in clinical trials
    Cantillo, E.
    Anderson, L.
    Robinson, W.
    GYNECOLOGIC ONCOLOGY, 2013, 131 (01) : 266 - 267
  • [20] Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer
    Iwase, Toshiaki
    Shrimanker, Tushaar Vishal
    Rodriguez-Bautista, Ruben
    Sahin, Onur
    James, Anjali
    Wu, Jimin
    Shen, Yu
    Ueno, Naoto T.
    CANCERS, 2021, 13 (11)
12345